14 results about "Stable angina" patented technology

The invention discloses an application of nitro fatty acid in preparation of a product for predicting, preventing and improving adverse cardiovascular events of patients with acute coronary syndrome. The invention provides application of nitro fatty acid in preparation of products for preventing and improving adverse cardiovascular events of ACS patients. According to the application, for the ACS patient, when the concentration of the 12-nitro conjugated linoleic acid in the body is larger than 0.196 ng / ml and the concentration of the 9-nitro conjugated linoleic acid is larger than 0.296 ng / ml, it is judged that the risk that the ACS patient is re-hospitalized and dead due to non-fatal myocardial infarction / unstable angina pectoris / blood supply reconstruction is low. By detecting the content of nitro fatty acid in a biological sample and supplementing nitro fatty acid, the occurrence rate of adverse events can be greatly reduced. Meanwhile, the invention further provides a detection method of nitro fatty acid, and the accuracy of biological sample detection is improved.

The present invention relates to the field of biomarker technology, and in particular to the LL‑37‑ApoB‑100 biomarker and its application. The present invention has discovered a biomarker LL‑37‑ApoB‑100 complex in blood and / or atheromatous plaques related to the prediction and diagnosis of coronary atherosclerosis / coronary heart disease. Antibodies are prepared using the marker, and coronary atherosclerosis or coronary atherosclerosis-related diseases can be predicted and diagnosed by enzyme-linked immunosorbent assay, and different subtypes of coronary heart disease such as coronary atherosclerosis and stable angina, unstable angina and acute myocardial infarction can be effectively identified. Compared with traditional coronary atherosclerosis or coronary heart disease markers, the biomarker has significant advantages such as higher sensitivity, higher specificity, faster and simpler detection, lower cost and less trauma.

The invention discloses a kidney-tonifying and spleen-tonifying traditional Chinese medicine composition as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10 to 40 parts of roasted turtle shell, 10 to 30 parts of herba taxilli, 10 to 20 parts of cortex eucommiae, 10 to 30 parts of semen cuscutae, 10 to 30 parts of herba cistanche, 10 to 30 parts of radix codonopsis, 10 to 30 parts of poria cocos, 10 to 30 parts of rhizoma polygoni cuspidati and 10 to 30 parts of rhizoma chuanxiong. The traditional Chinese medicine composition disclosed by the invention has the effects of tonifying kidney and spleen, dissipating blood stasis and relieving pain, and softening hardness to dissipate stagnation, is a proved recipe for clinical application for many years, is stable in curative effect, few in adverse reaction and good in healing, and provides an effective traditional Chinese medicine preparation for treating stable angina pectoris. During preparation of the traditional Chinese medicine composition, monarch drugs are pulverized and used as medicines, other medicines are extracted and concentrated, medicinal components are fully reserved, and the traditional Chinese medicine composition is simple in process, high in universality and suitable for large-scale production.

The invention discloses a Chinese medicine composition containing aconite for treating unstable angina pectoris, wherein the raw materials thereof are aconite, ginseng, American ginseng, pseudostellaria, yam, cassia twig, ophiopogon, schisandra, cornus officinalis, asparagus cochinchinensis, radix rehmanniae, spiny date seeds, keel, and oyster. The results of clinical efficacy observation tests confirm that the Chinese medicine composition of the invention can significantly improve the clinical symptoms of patients with unstable angina pectoris, significantly reduce the duration and frequency of their angina attacks, improve their cardiac function, resist myocardial oxidation, reduce stress response, antagonize ET‑1, and promote the recovery of vascular endothelial function.

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

The present application relates to a kind of traditional Chinese medicine composition for treating coronary atherosclerotic disease stable angina, the traditional Chinese medicine composition is made of the following weight parts of raw medicinal materials: Radix Bupleuri 10-14 parts, Ramulus Cinnamomi 3-7 parts, Herba Agrimoniae 13-17 parts, Salvia Miltiorrhiza 13-17 parts, Radix Paeoniae Alba 3-7 parts, Rhizoma Pinelliae Praeparatum 4-8 parts, Radix Scophularae 3-7 parts, Radix Ginseng 3-7 parts, Radix Glycyrrhizae 1-5 parts, Zingiber officinale 3-7 parts, Fructus Jujubae 4-8 parts.The present application also provides the application of traditional Chinese medicine composition in the preparation of medicine for treating coronary atherosclerotic disease stable angina.The treatment principle of the present application is: regulating liver and unblocking yang, regulating qi and activating blood.The drugs in the present application are used together, and the effect is enhanced, can regulate Ying and Wei, regulate liver qi, unblock chest yang, and unblock blood vessels, so as to achieve the effect of preventing and treating stable angina pectoris of coronary heart disease.The present application can effectively improve the angina pectoris symptoms of patients with stable angina pectoris of coronary heart disease, improve the quality of life of patients, has certain clinical value, and is worth further research and promotion.

This invention discloses a multifunctionalized pyridine compound, its preparation method, and its applications, belonging to the fields of pharmaceutical intermediates and organic synthesis. The invention uses α-allyl-p-toluenesulfonylmethylene isonitrile and substance A as raw materials, and a free radical cyclization reaction is carried out under the action of a catalyst to obtain a highly functionalized pyridine compound, as shown in formula (Ⅰ). Substance A is phenylboronic acid, cyclohexylboronic acid, [1,1'-biphenyl]-4-boronic acid, p-methylphenylboronic acid, m-methylphenylboronic acid, o-methylphenylboronic acid, p-cyanophenylboronic acid, thiophene-3-boronic acid, or cyclopropylboronic acid. The method of this invention not only has very broad substrate tolerance, inexpensive and readily available raw materials, and a simple reaction process suitable for large-scale synthesis, but also provides a new method for pharmaceutical chemical synthesis. Furthermore, due to the high functionalization and special structure of the pyridine compound, it exhibits better efficacy in treating chronic stable angina pectoris, central respiratory depression and circulatory failure, and in the treatment of various organoiodinated phosphate poisonings.

The invention relates to a heart-nourishing Damwaitomixic pill and a preparation method thereof. The heart-nourishing Damwaemixic pill comprises a pill core, wherein the pill core comprises mixed powder, clear paste and an adhesive; the mixed powder comprises medicine powder and dry auxiliary materials; the adhesive is prepared according to the following steps: mixing slurry A and slurry B; the pulp A comprises starch and a first batch of apple pulp; the pulp B comprises a second batch of apple pulp subjected to heating treatment; the mass ratio of the apple pulp to the starch is 390: (78-97.5); the mass ratio of the medicinal powder to the sum of the dry auxiliary materials and the starch is 1: (0.6-1); the ratio of the sum of the mass of the medicinal powder and the starch to the sum of the mass of the clear paste and the apple pulp is 1: (0.7-0.9). The heart-nourishing Damwaitomixic pill disclosed by the invention is low in sugar content, proper in disintegration time, good in stability and convenient to store and carry, and can be used as a medicine for treating or preventing stable angina pectoris and chronic heart failure.

The invention discloses a traditional Chinese medicine composition for eliminating phlegm and dispersing blood stasis and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 10-30 parts of rhizoma chuanxiong, 10-30 parts of cortex moutan, 10-30 parts of radix paeoniae rubra, 10-30 parts of radix salviae miltiorrhizae, 10-30 parts of radix acanthopanacis semticosi, 10-30 parts of fructus trichosanthis, 10-30 parts of allium macrostemon, 10-40 parts of raw radix astragali, 10-20 parts of rhizoma polygoni cuspidati and 10-20 parts of lotus leaves. The traditional Chinese medicine composition disclosed by the invention has the effects of simultaneously treating phlegm and blood stasis and eliminating phlegm and dispersing blood stasis, and is a proved recipe for years of clinical application for treating chest stuffiness and phlegm and blood stasis syndrome, clinical observation shows that the traditional Chinese medicine composition is stable in curative effect, few in adverse reaction and good in healing, and an effective traditional Chinese medicine preparation is provided for treating stable angina pectoris and phlegm and blood stasis syndrome. When the traditional Chinese medicine composition is prepared, volatile components are extracted at the same time, traditional Chinese medicine effect components of ligusticum wallichii and other medicines are fully reserved, and meanwhile the process is simple, high in universality and suitable for large-scale production.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.

The invention relates to a polypeptide and application thereof in preparation of related products for inhibiting myocardial remodeling. The CTRP9 229-333 polypeptide can improve the cardiac function of a patient with cardiac diseases, so that the CTRP9 229-333 polypeptide can be used for treating myocardial remodeling diseases caused by stable angina pectoris, unstable angina pectoris, myocardial infarction, chronic ischemic heart disease, coronary spasmodic heart disease, myocarditis and the like. Besides, the CTRP9 229-333 polypeptide not only can inhibit cardiac fibrosis, but also can inhibit myocardial hypertrophy, and the myocardial cell apoptosis inhibiting capacity of the CTRP9 229-333 polypeptide is higher than that of the full-length protein CTRP9. Compared with the full-length protein CTRP9, the CTRP9 229-333 polypeptide has remarkable advantages in the aspects of absorption efficiency, biological activity, nutritional value, safety, applicability and the like compared with the protein. Due to the advantages, the polypeptide has wide application prospects in the fields of nutritional supplement, health care, disease treatment and the like.

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

This application discloses a method, apparatus, device, and storage medium for pushing cardiac rehabilitation prescriptions to patients with stable angina pectoris. The method includes: acquiring original patient medical data from at least one external subsystem via an asynchronous parallel interface; determining snapshot information of the patient's status under various predefined cardiac rehabilitation rules based on the original patient medical data; correcting at least one of the exercise prescription parameters, medication prescription parameters, nutritional prescription parameters, psychological prescription parameters, and smoking cessation prescription parameters in the corresponding rehabilitation prescription based on the snapshot information of the patient's status, thereby determining rehabilitation prescription information; predicting the correction scheme and resource scheduling scheme for rehabilitation activities against preset long-term goals in the corresponding event nodes based on the original patient data and rehabilitation prescription information, thereby determining correction prescription information and resource scheduling prescription information; and pushing the rehabilitation prescription information, correction prescription information, and resource scheduling prescription information to multiple terminals for visual display.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.